[Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
The effectiveness of serum CEA (56 cases), CA-19-9 (53 cases) and TPA (48 cases) in patients with colorectal cancer has been evaluated. The preoperative sensitivity and specificity of CEA and CA 19-9 were found to be almost the same in level but the level of TPA was low. In 20 cases recurrent, the sensitivity of the marker was 66.7% in the liver, 60% in the lung, and 66.7% in the local recurrence of primary foci. In these recurrent cases, serum CEA in initially elevated to 65%, CA 19-9 to 25%, and TPA to only 10%. In diagnostic rate imaging or in our clinical findings, however, the frequency was almost the same as tumor markers.
Nishida
O
O
1st Dept. of Surgery, Hokkaido Univ. School of Med.
Shiroto
H
H
Satoh
N
N
Nakajima
Y
Y
Manabe
K
K
Kondoh
Y
Y
Sano
F
F
Uchino
J
J
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D010455:Peptides / Q000032:analysis*; D011863:Radioimmunoassay / Q000379:methods; D019396:Tissue Polypeptide Antigen
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen